Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials
Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials
Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.